Our results are in agreement with previous clinical studies who have shown that the detection of CK-19(+) mRNA cells in the peripheral blood of patients with operable breast cancer before, during and after adjuvant treatment is an independent prognostic factor associated with an increased risk of disease relapse and shorter survival16–18,44,45. This evidence concerns the gene KRT19 and breast carcinoma.